Tpharm.info


Metformin mechanism of action





Glucophage, Glucophage XR (Metformin Hcl) Drug Information

7/17/2014
01:36 | Author: Emma Coleman

Metformin mechanism of action
Glucophage, Glucophage XR (Metformin Hcl) Drug Information

Its pharmacologic mechanisms of action are different from other classes of oral antihyperglycemic agents. Metformin decreases hepatic glucose production.

Find out what women really need.

In contrast to sulfonylureas, body weight of individuals on GLUCOPHAGE tended to remain stable or even decrease somewhat (see Tables 2 and 3).

Following a single oral dose of GLUCOPHAGE XR, Cmax is achieved with a median value of 7 hours and a range of 4 to 8 hours. Peak plasma levels are approximay 20% lower compared to the same dose of GLUCOPHAGE, however, the extent of absorption (as measured by AUC) is similar to GLUCOPHAGE.

Table 5: Combined GLUCOPHAGE/Insulin vs Placebo/Insulin Summary of Mean Changes from Baseline in HbA 1c and Daily Insulin Dose GLUCOPHAGE/ Insulin (n=26) Placebo/ Insulin (n=28) Treatment Difference Mean ± SE Hemoglobin A 1c (%) Baseline 8.95 9.32 Change at FINAL VISIT –2.10 –1.56 –0.54 ± 0.43a Insulin Dose (U/day) Baseline 93.12 94.64 Change at FINAL VISIT –0.15 15.93 –16.08 ± 7.77b a Statistically significant using analysis of covariance with baseline as covariate (p=0.04) Not significant using analysis of variance (values shown in table) b Statistically significant for insulin (p=0.04).

At steady state, the AUC and Cmax are less than dose proportional for GLUCOPHAGE XR within the range of 500 to 2000 mg administered once daily.

Comments (1)Read more



Cellular and molecular mechanisms of metformin an overview

5/16/2014
03:32 | Author: Emma Coleman

Metformin mechanism of action
Cellular and molecular mechanisms of metformin an overview

Considerable efforts have been made since the 1950s to better understand the cellular and molecular mechanisms of action of metformin, a potent.

Warning: The NCBI web site requires JavaScript to function. more.

Images from this publication. See all images (3) Free text.

Generate a file for use with external citation management software.

National Center for Biotechnology Information, U.S. National Library of Medicine 8600 Rockville Pike, Bethesda MD, 20894 USA.

Considerable efforts have been made since the 1950s to better understand the cellular and molecular mechanisms of action of metformin, a potent antihyperglycaemic agent now recommended as the first-line oral therapy for T2D (Type 2 diabetes). The main effect of this drug from the biguanide family is to acuy decrease hepatic glucose production, mostly through a mild and transient inhibition of the mitochondrial respiratory chain complex I. In addition, the resulting decrease in hepatic energy status activates AMPK (AMP-activated protein kinase), a cellular metabolic sensor, providing a generally accepted mechanism for the action of metformin on hepatic gluconeogenesis. The demonstration that respiratory chain complex I, but not AMPK, is the primary target of metformin was recently strengthened by showing that the metabolic effect of the drug is preserved in liver-specific AMPK-deficient mice. Beyond its effect on glucose metabolism, metformin has been reported to restore ovarian function in PCOS (polycystic ovary syndrome), reduce fatty liver, and to lower microvascular and macrovascular complications associated with T2D. Its use has also recently been suggested as an adjuvant treatment for cancer or gestational diabetes and for the prevention in pre-diabetic populations. These emerging new therapeutic areas for metformin will be reviewed together with recent findings from pharmacogenetic studies linking genetic variations to drug response, a promising new step towards personalized medicine in the treatment of T2D.

Comments (0)

Metforminmdashmode of action and clinical implications for

3/15/2014
05:48 | Author: David Perry

Mechanism of action in pharmacology
Metforminmdashmode of action and clinical implications for

The centre of metformin's mechanism of action is the alteration of the energy metabolism of the cell. Metformin exerts its prevailing.

Comments (0)

Metformin in the treatment of adults with type 2 diabetes mellitus

11/24/2014
03:16 | Author: Lauren Ross

Metformin mechanism of action
Metformin in the treatment of adults with type 2 diabetes mellitus

The molecular mechanisms of metformin action are not fully known. Activation of the enzyme AMP-activated protein kinase (AMPK) appears to.

Subscribers log in here Related articles Related Searches Topic Outline INTRODUCTION.

The pharmacology, efficacy, and side effects of metformin for the treatment of diabetes will be reviewed here. A general discussion of initial pharmacologic treatment of type 2 diabetes and the role of metformin in the prevention of diabetes, in the treatment of polycystic ovary syndrome, and in gestational diabetes are reviewed separay. (See "Initial management of blood glucose in adults with type 2 diabetes mellitus" and "Prevention of type 2 diabetes mellitus", section on 'Metformin' and "Metformin for treatment of the polycystic ovary syndrome" and "Gestational diabetes mellitus: Glycemic control and maternal prognosis", section on 'Metformin'.

Comments (4)Read more

DrugBank Metformin (DB00331)

9/23/2014
01:40 | Author: David Perry

Metformin mechanism of action
DrugBank Metformin (DB00331)

Metformin may induce weight loss and is the drug of choice for. Mechanism of action, Metformin's mechanisms of action differ from other.

Metformin is not metabolized.

654 L for metformin 850 mg administered as a single dose. The volume of distribution following IV administration is 63-276 L, likely due to less binding in the GI tract and/or different methods used to determine volume of distribution.

Jorn Moeckel, Rolf-Dieter Gabel, Heinrich Woog, “Pharmaceutical preparation containing metformin and a process for producing it.” U.S. Patent US5955106, issued October, 1991. Kind: protein Organism: Human Pharmacological action: yes Actions: inducer Kind: protein Organism: Human Pharmacological action: unknown Actions: substrate inhibitor Kind: protein Organism: Human Pharmacological action: unknown Actions: substrate inhibitor Kind: protein Organism: Human Pharmacological action: unknown Actions: substrate Kind: protein Organism: Human Pharmacological action: unknown Actions: inhibitor Kind: protein Organism: Human Pharmacological action: unknown Actions: substrate.

Metformin is a biguanide antihyperglycemic agent used for treating non-insulin-dependent diabetes mellitus ( NIDDM ).

Comments (5)Read more